Inform, Empower, Connect

Doxorubicin Hydrochloride Liposome Combined With Irinotecan Versus VIT Regimen in the Treatment of Pediatric Rhabdomyosarcoma

Last Update Posted : 2022-07-14

The aim of the trial

  • This multicenter, randomized, controlled, open-label, prospective clinical trial was designed to evaluate the efficacy and safety of doxorubicin hydrochloride liposome injection in combination with irinotican (AI regimen) versus VIT regimen in the treatment of first relapsed and refractory pediatric rhabdomyosarcoma.
Country
-
Locations
-
Trial Type
Interventional
Trial Phase
Phase 2
Trial Status
Not yet recruiting
Minimum age
6 Months
Maximum age
18 Years
Key Contact
zhang Yizhuo, PhD, 020-87342460, zhangyzh@sysucc.org.cn,
Clinical Trial ID
NCT05457829

Key Information

  • -

How the treatment works

  • Q3W, 2 cycles.
  • Visit our drugs and interventions page to find out more about this treatment, including how it works and what it’s used for.

Disclaimer

  • The Osteosarcoma Now trial finder is intended to supplement, not replace, your healthcare team. Patients should always discuss a clinical trial with their healthcare team.  If a patient is eligible for a trial the trial team will be able to provide more in-depth information about the trial so the patient can make an informed decision before taking part. Trial information has been sourced from www.clinicaltrials.gov. The content is then reviewed weekly by the Osteosarcoma Now team. All the trials also have a patient-friendly summary and key information section written by the team at Osteosarcoma Now. We have also included a description of the medications being used in the trial and have added some explainer text (In brackets) to the ‘who is this trial (not) for’ sections. To the best of our ability the clinical trial database is up-to-date and accurate however, we cannot assume any liability for the accuracy or completeness of the information.